However, while early clinical studies of combined PD1 and IDO1 inhibition in metastatic melanoma have shown promising results [36], another randomized clinical study has failed to demonstrate a more significant clinical benefit from this combination than PD1 inhibition alone [37]. Here, IDO1 is linked to metastatic melanoma.